Helicobacter pylori bacterium is the cause of more than 90% duodenal and 80% gastric ulcers, and the major risk factor for gastric carcinoma and primary gastric lymphoma. Gastric cancer is the second most common cause of cancer-related deaths in the world. Currently available antibiotic therapy for treating H. pylori infection has multiple disadvantages. Thus, development of new, more efficient antimicrobial therapeutic agent against H. pylori, is a necessity. University of Novi Sad Faculty of Sciences (UNSPMF) and Hungarian Academy of Sciences, Biological Research Center (MTA SZBK) have developed a joint initiative to bring Serbian and Hungarian researchers together with the aim to develop a new, natural-product-based formulation targeting H. pylori.
During the 18-months period, a number of essential oils will be isolated, chemically characterized, and their in vitro and in vivo antimicrobial activity will be tested in order to create an optimal formulation, with the highest activity and the least adverse effects. The main project output will be new drug formulation that will be patented, as a first step towards it mass production and application in treatment of H. pylori infected patients in cross-border region and worldwide. SMEs in the field of pharmaceutical industry, that will be offered a new product for mass production and distribution, will also profit from the project results. Partner institutions will benefit from the results of the project, since their research capacities will be improved, visibility heightened, and new links will be established, helping the integration of both institutions into European Research Area and making them more competitive in application for various nationally and EU-funded projects.